HC Wainwright Reaffirms “Buy” Rating for Emergent BioSolutions (NYSE:EBS)

HC Wainwright restated their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a report released on Tuesday morning,Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently weighed in on the company. StockNews.com upgraded Emergent BioSolutions from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Benchmark upped their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Stock Performance

Shares of NYSE EBS opened at $10.19 on Tuesday. The company has a market cap of $551.82 million, a PE ratio of -2.48 and a beta of 1.60. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. Emergent BioSolutions has a 12-month low of $1.42 and a 12-month high of $15.10. The stock has a 50 day simple moving average of $9.27 and a 200-day simple moving average of $9.24.

Emergent BioSolutions (NYSE:EBS) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.88. The firm had revenue of $293.80 million during the quarter, compared to the consensus estimate of $328.72 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same period in the prior year, the firm posted ($1.44) earnings per share. On average, equities research analysts forecast that Emergent BioSolutions will post -0.63 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. State Street Corp raised its stake in Emergent BioSolutions by 864.7% during the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after purchasing an additional 1,713,200 shares during the period. Oak Hill Advisors LP acquired a new stake in Emergent BioSolutions during the 3rd quarter valued at $9,296,000. Millennium Management LLC raised its stake in Emergent BioSolutions by 5.8% during the 2nd quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company’s stock valued at $6,454,000 after purchasing an additional 52,144 shares during the period. American Century Companies Inc. raised its stake in Emergent BioSolutions by 240.9% during the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after purchasing an additional 623,201 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in Emergent BioSolutions by 3.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 766,537 shares of the biopharmaceutical company’s stock valued at $7,328,000 after purchasing an additional 24,985 shares during the period. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.